By: Russ Conroy
Two teams of multiple myeloma experts debate the use of early CAR T-cell therapies and bispecific antibodies based on key trial data and various hot topics.
Russ Conroy is an Assistant Editor for CancerNetwork. He focuses on various aspects of medicine and healthcare, including oncology, hematology, immunotherapy, and patient care, while also exploring topics like pharmaceutical regulation and medical equipment innovations. Russ's work has been featured in notable publications such as AJMC - The American Journal of Managed Care, Dermatology Times, and Oncology Nursing News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Russ Conroy's articles primarily focus on healthcare and pharmaceutical topics, with a significant emphasis on citing data to support the information provided. Given this approach, Russ would likely be interested in pitches that provide access to new or exclusive scientific research findings related to cancer treatment, leukemia, breast cancer, multiple myeloma, and immunotherapy.
Since Russ focuses heavily on citing data and presenting evidence-based information in his articles, he may be particularly responsive to pitches from experts who can provide insights based on the latest clinical trials or research studies within the field of oncology and cancer treatment. Additionally, sources who can offer contextualized expert commentary supported by robust scientific evidence could capture his interest.
While there is no specific geographic focus mentioned for Russ Conroy’s coverage attributes or article titles provided here; it appears that he covers a broad range of international developments in healthcare and pharmaceuticals without being limited to any particular region.
This information evolves through artificial intelligence and human feedback. Improve this profile .